Cordiotoxicity of Polychemotherapy for Hematological Malignancies
Keywords:
Cardiotoxicity, polychemotherapy, hematological malignancies, anthracyclines, oxidative stressAbstract
Cardiotoxicity is a significant and potentially life-threatening complication of polychemotherapy used in the treatment of hematological malignancies. The cumulative impact of chemotherapy agents, particularly anthracyclines and alkylating agents, can lead to various forms of cardiac dysfunction, ranging from asymptomatic left ventricular dysfunction to overt heart failure. The mechanisms of chemotherapy-induced cardiotoxicity include oxidative stress, mitochondrial dysfunction, and direct damage to cardiac myocytes. This article explores the incidence, pathophysiology, and clinical manifestations of cardiotoxicity in patients undergoing polychemotherapy for hematological malignancies. It also reviews strategies for early detection, prevention, and management, including the use of cardioprotective agents and modifications to treatment protocols. Emphasis is placed on the importance of continuous cardiac monitoring and the development of individualized treatment plans to minimize cardiac risk without compromising the efficacy of chemotherapy. Understanding the balance between effective cancer treatment and cardiotoxic risk is crucial for improving patient outcomes in the management of hematological malignancies.
References
O’Brien, S. M., & Kantarjian, H. M. (2018). Cardiotoxicity associated with anthracyclines: The role of cardioprotective strategies. Leukemia & Lymphoma, 59(1), 18-25. https://doi.org/10.1080/10428194.2017.1387034
Armenian, S. H., & Hunter, L. (2015). Cardiovascular disease in survivors of hematologic malignancies: Risk factors and management. Blood Reviews, 29(4), 245-255. https://doi.org/10.1016/j.blre.2015.04.002
von Hoff, D. D., et al. (2000). Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 132(4), 286-293. https://doi.org/10.7326/0003-4819-132-4-200002150-00001
Van Dalen, E. C., et al. (2013). Cardiovascular effects of anthracycline therapy in children and adolescents: A systematic review. European Journal of Cancer, 49(7), 1570-1577. https://doi.org/10.1016/j.ejca.2012.10.008
Lipshultz, S. E., et al. (2013). Long-term consequences of anthracycline therapy for acute lymphoblastic leukemia: A pediatric perspective. Pediatrics, 131(4), e1064-e1071. https://doi.org/10.1542/peds.2012-3251
Jain, S. K., & Kaur, J. (2020). Mechanisms of chemotherapy-induced cardiotoxicity: A focus on anthracyclines. Cardiology Research and Practice, 2020, Article ID 8796382. https://doi.org/10.1155/2020/8796382
Zuckerman, H., & Zimran, A. (2021). Cardiac monitoring in patients receiving anthracycline chemotherapy: Recommendations and guidelines. American Journal of Hematology, 96(1), 123-130. https://doi.org/10.1002/ajh.26125
Steinberg, J. S., & Mehra, M. (2015). The role of cardiac imaging in the diagnosis of chemotherapy-induced cardiotoxicity. Circulation: Cardiovascular Imaging, 8(5), e003062. https://doi.org/10.1161/CIRCIMAGING.115.003062
Scully, M. A., & Neilan, T. G. (2020). Cancer therapy-related cardiac dysfunction: An emerging problem. Current Opinion in Cardiology, 35(4), 422-429. https://doi.org/10.1097/HCO.0000000000000710
Moslehi, J. J., & Ewer, M. S. (2010). Mechanisms of cardiotoxicity associated with anthracycline anticancer agents. Nature Reviews Cardiology, 7(4), 209-220. https://doi.org/10.1038/nrcardio.2010.5
Gazkhanovna, M. A., Makhmatovich, A. K., & Utkirovich, D. U. (2022). Clinical efficacy of extracorporeal and intravascular hemocorrection methods in psoriasis. ACADEMICIA: An International Multidisciplinary Research Journal, 12(2), 313-318.
Ruziboeva, O. N., Abdiev, K. M., Madasheva, A. G., & Mamatkulova, F. K. (2021). Modern Methods Of Treatment Of Hemostasis Disorders In Patients With Rheumatoid Arthritis. Ученый XXI века, 8.
Madasheva, A. G., Yusupova, D. M., & Abdullaeva, A. A. EARLY DIAGNOSIS OF HEMOPHILIA A IN A FAMILY POLYCLINIC AND THE ORGANIZATION OF MEDICAL CARE. УЧЕНЫЙ XXI ВЕКА, 37.
